Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
NCT00801125 · Biogen · PHASE4 · withdrawn · last registry update 2016-06-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study sponsor decided to withdraw the current study prior to enrollment of first participant.” | – | Registry record, Biogen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-06-09Results posted on the registry: Biogen, natalizumab + fingolimod (NCT02342704)
- 2017-06-09Also stopped (terminated): Biogen, natalizumab + fingolimod (NCT02342704)
- 2017-06-05Results posted on the registry: Biogen, natalizumab (NCT02241785)
- 2017-06-05Also stopped (terminated): Biogen, natalizumab (NCT02241785)
- 2017-03-31Results posted on the registry: University of South Florida, Tysabri ® (Natalizumab) (NCT01455220)
- 2017-03-08Also stopped (withdrawn): Takeda, Vedolizumab + Placebo (NCT03035058)
- 2017-02-01Results posted on the registry: Takeda, Vedolizumab SC + Vedolizumab IV (NCT02163421)
- 2017-01-27Phase 3 first posted: Takeda, Vedolizumab + Placebo (NCT03035058)
- 2016-12-29Also stopped (withdrawn): University of Texas Southwestern Medical Center, methylprednisolone (NCT01710228)
- 2016-11-03Phase 3 first posted: Medical College of Wisconsin, Tacrolimus + Vedolizumab (NCT02954159)
- 2016-09-23Also stopped (withdrawn): Takeda, Vedolizumab intravenous injection + Vedolizumab subcutaneous injection (NCT02913508)
- 2016-08-29Phase 3 first posted: Biogen, Daclizumab (NCT02881567)
- 2016-07-18Also stopped (terminated): Biogen, natalizumab + placebo (NCT00083759)
- 2016-07-15Also stopped (terminated): Biogen, Natalizumab (NCT00297232)
- 2016-07-01Results posted on the registry: Biogen, natalizumab + Placebo (NCT01955707)
- 2016-06-16Also stopped (terminated): Biogen, natalizumab (NCT00831649)
- 2016-01-14Results posted on the registry: Biogen, natalizumab (NCT01416155)
- 2015-12-02Phase 3 first posted: Takeda, Vedolizumab SC (NCT02620046)
- 2015-11-23Phase 3 first posted: Takeda, Vedolizumab SC 108 mg + Placebo (NCT02611817)
- 2015-11-23Phase 3 first posted: Takeda, Vedolizumab 300 mg IV + Placebo IV (NCT02611830)
- 2015-07-29Results posted on the registry: Biogen, natalizumab IV + natalizumab SC (NCT01405820)
- 2015-07-14Phase 3 first posted: Takeda, Vedolizumab + Adalimumab placebo (NCT02497469)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision